Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AWARD-2: once-weekly LY2189265 versus insulin glargine in type 2 diabetes
2009-014803-30Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dulaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to week 52. Started Nov 2009; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-014803-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014803-30.